Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Deferred Revenue (2016 - 2021)

Syndax Pharmaceuticals has reported Current Deferred Revenue over the past 7 years, most recently at $12.4 million for Q3 2021.

  • Quarterly results put Current Deferred Revenue at $12.4 million for Q3 2021, up 717.4% from a year ago — trailing twelve months through Sep 2021 was $12.4 million (up 717.4% YoY), and the annual figure for FY2020 was $1.5 million, changed 0.0%.
  • Current Deferred Revenue for Q3 2021 was $12.4 million at Syndax Pharmaceuticals, up from $1.5 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for SNDX hit a ceiling of $12.4 million in Q3 2021 and a floor of $1.2 million in Q1 2017.
  • Median Current Deferred Revenue over the past 5 years was $1.5 million (2018), compared with a mean of $2.0 million.
  • Biggest five-year swings in Current Deferred Revenue: dropped 3.56% in 2018 and later soared 717.4% in 2021.
  • Syndax Pharmaceuticals' Current Deferred Revenue stood at $1.6 million in 2017, then decreased by 3.56% to $1.5 million in 2018, then changed by 0.0% to $1.5 million in 2019, then changed by 0.0% to $1.5 million in 2020, then soared by 717.4% to $12.4 million in 2021.
  • The last three reported values for Current Deferred Revenue were $12.4 million (Q3 2021), $1.5 million (Q2 2021), and $1.5 million (Q1 2021) per Business Quant data.